HIGHLIGHTS
We describe the experience of our hospital, UMAE 25 IMSS in Monterrey NL, Mexico, of 11 years performing hematopoietic stem-cell transplantation (HSCT) in pediatric patients with primary immune deficiencies.
We report the clinical features, origin, diagnoses, treatment and outcome of 19 patients with 8 PID diagnoses who underwent HSCT, with a 79% survival rate, 21% GVHD prevalence, 47% stable chimerism, and 58% of complete immune reconstitution.
Post-transplant cyclophosphamide has been proven effective as anti-GVHD prophylaxis. Despite all our grafts coming from umbilical cord and haploidentical donors, we were able to prevent GVHD by using post-transplant cyclophosphamide.
In Mexico and Latin America, we need better local and regional donor registries. We can achieve encouraging positive results despite resource scarcity and other regional limitations.